By FSD Pharma on Wednesday, 04 December 2019
Category: Vertically Integrated

FSD Pharma 'hunkering down' on grow facility and 'doubling down' on biosciences effort

viewFSD Pharma

Inc () (OTCMKTS:FSDDF) CEO Raza Bokhari reveals 3Q highlights for the medically-focused cannabis company.

Bokhari says the Canadian company is 'hunkering down' on its cannabis grow facility and 'doubling down' on its biosciences effort, advancing its Phase 1 safety trials for its lead drug candidate PP 101 micro-PEA.

CSE:HUGE

Market: CSE
Market Cap: $63.39 m
Follow

View company profile

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Most read

FSD Pharma rings the Nasdaq opening bell in 'exciting and momentous moment'

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) CEO Raza Bokhari, who runs the pharmaceutical cannabis research company, rang the Nasdaq opening bell together with with members of the board, leadership team, early investors, and others. Bokhari says it was an 'exciting and momentous moment' for the...

1 week, 2 days ago

2 min read

Related Posts